Results 191 to 200 of about 121,345 (281)

Chewing tobacco product [PDF]

, 2022
openaire   +1 more source

Methods of cessation of traditional and novel tobacco and nicotine product use: a systematic review to support nicotine-related prevention strategies.

Znotiņa, Inga, Vanadzins, Ivars, Straume, Ilze, Paegle, Diana Inga, Samel-Kowalik, Piotr, Miller, Natalia   +5 more
openalex   +1 more source

Sustainability in Analytical Chemistry Illustrated by Pharmaceutical Nitrosamine Testing

ELECTROPHORESIS, EarlyView.
ABSTRACT Following the valsartan scandal in 2018, the testing of drug substances and drug products for N‐nitrosamines has become a critical and mandatory quality control measure. The European Pharmacopoeia chapter 2.5.42 currently describes three analytical methods for this purpose: HPLC–MS/MS, GC–MS, and GC–MS/MS.
Felix Bredendiek, Sebastian Schmidtsdorff, Maria Kristina Parr   +2 more
wiley   +1 more source

Emissions from conventional and electronic waterpipes relative to cigarettes and a heated tobacco product. [PDF]

Sci Rep
Wilkinson PJ, Clarke A, Fearon IM, Barry R.   +3 more
europepmc   +1 more source

A randomised, controlled, two-Centre open-label study in healthy Japanese subjects to evaluate the effect on biomarkers of exposure of switching from a conventional cigarette to a tobacco heating product

, 2017
Nathan Gale, Michael McEwan, Alison Eldridge, N. Sherwood, Edward Bowen, Simon McDermott, Emma Holmes, Andrew Hedge, Stuart Hossack, Oscar M. Camacho, Graham Errington, John McAughey, James J. Murphy, Chuan Liu, Christopher Proctor, Ian M. Fearon   +15 more
openalex   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Beneath the Label - Evaluating the FDA Approval of Copenhagen Classic Snuff as a Modified Risk Tobacco Product. [PDF]

HCA Healthc J Med
Grabie Y, Chowdhury T, Acharya S.
europepmc   +1 more source

Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study (ELUCID)

Epilepsia Open, EarlyView.
Abstract Objective Late‐onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10%–25% of individuals with LoUE develop dementia within 3–4 years following their first seizure.
Alice D. Lam, Emily L. Johnson, Rani A. Sarkis, Leah J. Blank, Tyler E. Gaston, Mouhsin M. Shafi, Rodrigo Zepeda, Kyle R. Pellerin, Nathalie Jette, Douglas N. Greve, Lori B. Chibnik, Rebecca E. Amariglio, Gad A. Marshall, M. Brandon Westover   +13 more
wiley   +1 more source

Heated Tobacco Product Spread and Hospitalizations for Acute Coronary Syndrome in Japan.

JAMA Netw Open
Iwanaga Y, Nakai M, Miyamoto Y, Hirano T, Fujiwara H.   +4 more
europepmc   +1 more source

Cardiovascular Health Effects and Synthetic Cooling Agents in E-Cigarettes Labeled as "Clear" Marketed in Massachusetts After the Tobacco Product Flavoring Ban. [PDF]

J Am Heart Assoc
Minetti ET, Erythropel HC, Keith R, Davis DR, Zimmerman JB, Krishnan-Sarin S, Hamburg NM.   +6 more
europepmc   +1 more source